Gene signature predictor of dose-response to prostate radiation: Validation of PORTOS in phase III trials. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results